Roche Holding AG, of Basel, Switzerland, said its Genentech unit received FDA approval for Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection for the treatment of adults with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL) and previously untreated and previously treated chronic lymphocytic leukemia (CLL). Read More
Spring Bank Pharmaceuticals Inc., of Hopkinton, Mass., priced its public offering of about 2.9 million shares at $13 apiece for gross proceeds of about $37.5 million. Read More
In a bipartisan effort, four senators introduced the STRONGER Patents Act to protect and support innovators and ensure that the U.S. patent system protects the intellectual property rights of inventors. Read More
The Senate health care reform bill debuted to a waiting and somewhat hostile Washington and, as expected, the legislation retains the repeal of the tax on medical devices and diagnostics found in the House bill. The language in the Senate bill is seen as little more than a draft of what will eventually go to the Senate floor for a vote, however, a vote that most likely will be held under budget reconciliation rules. Read More
DUBLIN – After 18 months in stealth mode, Montreal-based Repare Therapeutics Inc. has emerged with $68 million in series A funding and serious ambitions to become a leader in identifying small-molecule drugs that act on novel targets identified through CRISPR-based induction and screening of mutations that give rise to synthetic lethality. Read More
SAN DIEGO – Ambitious venture funds from Russia, China and India are seeking a growing stake in U.S. companies, creating new access to capital for startups. Though offering value beyond money to both investors and the recipients of their funds, international venture capitalists speaking at BIO 2017 said cultural and political frictions can still create challenges. Read More
DUBLIN – Novartis AG looks to be on course to add another significant product to its portfolio of cardiovascular drugs following a positive readout from the Cantos phase III cardiovascular outcomes trial of its interleukin-beta1 (IL-beta1) inhibitor, Ilaris (canakinumab). Read More
SAN DIEGO – As scientists and business leaders discussed innovation, valuation, transformative therapies and coming epidemics in various rooms throughout the San Diego Convention Center, something different occurred in Room 5B on Wednesday afternoon during BIO's International Convention. Read More
Biopharmx Corp., of Menlo Park, Calif., said data of a previously disclosed phase IIb trial testing BPX-01, a topical hydrophilic gel formulation of the antibiotic minocycline, in patients with acne vulgaris will be presented at the Alabama Dermatology Society's Summer Symposium. Read More
